Industries > Pharma > Drugs of Abuse Testing Market Report 2021-2031
Drugs of Abuse Testing Market Report 2021-2031
Forecasts by Product Type (Analyzers, Rapid Testing Devices, Consumables, and Laboratory Services), by Sample Type (Saliva, Breath, Urine, Blood, Hair, Sweat, and Others), by Testing Type (Onsite Screening Testing, and Laboratory Drug Testing), by Drug Type (Alcohol, Cannabis, Cocaine, Opioids, Amphetamine, LSD, and Others), by Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), by End User (Hospitals, Workplaces & Schools, Criminal Justice Systems & Law Enforcement Agencies, Diagnostics Laboratories, On-the-spot Testing, Forensic Laboratories, Specialty Clinics, and Others), by Distribution Channel (Direct Tender, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios
Drugs of Abuse Testing Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Drugs of Abuse Testing is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 250+ page report provides 480+ tables and 460+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Drugs of Abuse Testing Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By Product Type
• Analyzers
o Immunoassay Analyzers
o Chromatographic Devices
o Breath Analyzers
• Rapid Testing Devices
o Urine Testing Devices
o Oral Fluid Testing Devices
• Consumables
o Assay kits
o Sample collection cups
o Calibrators and controls
o Fluid Collection Devices
o Others
• Laboratory Services
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By Sample Type
• Saliva
• Breath
• Urine
• Blood
• Hair
• Sweat
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By Testing Type
• Onsite Screening Testing
• Laboratory Drug Testing
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By Drug Type
• Alcohol
• Cannabis
• Cocaine
• Opioids
• Amphetamine
• LSD
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By Patient Demographics
• Geriatric Patient
• Adult Patient
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By End User
• Hospitals
• Workplaces & Schools
• Criminal Justice Systems & Law Enforcement Agencies
• Diagnostics Laboratories
• On-the-spot Testing
• Forensic Laboratories
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Drugs of Abuse Testing Market By Distribution Channel
• Direct Tender
• Retail Sales
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Drugs of Abuse Testing Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Drugs of Abuse Testing Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Drugs of Abuse Testing Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Drugs of Abuse Testing Market, with forecasts for Get our report today Drugs of Abuse Testing Market Forecast 2021-2031: By Product Type, Sample Type, Testing Type, Drug Type, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Drugs of Abuse Testing market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Drugs of Abuse Testing Market. Some of the company’s profiled in this report include
• F. Hoffmann-La Roche AG
• Siemens Healthineers (Siemens AG)
• Thermo Fisher Scientific, Inc.
• Abbott
• Bio-Rad Laboratories Inc.
• Drgerwerk ag & co. Kgaa
• Shimadzu Corporation
• Laboratory Corporation of America Holdings
• Danaher
• Express Diagnostics International, Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Drugs of Abuse Testing Market Report 2021-2031: Forecasts by Product Type (Analyzers, Rapid Testing Devices, Consumables, and Laboratory Services), by Sample Type (Saliva, Breath, Urine, Blood, Hair, Sweat, and Others), by Testing Type (Onsite Screening Testing, and Laboratory Drug Testing), by Drug Type (Alcohol, Cannabis, Cocaine, Opioids, Amphetamine, LSD, and Others), by Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), by End User (Hospitals, Workplaces & Schools, Criminal Justice Systems & Law Enforcement Agencies, Diagnostics Laboratories, On-the-spot Testing, Forensic Laboratories, Specialty Clinics, and Others), by Distribution Channel (Direct Tender, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Drugs of Abuse Testing Market
2.1. Drugs of Abuse Testing Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Application Submarkets Definitions
3. Drugs of Abuse Testing Market Overview
3.1. Global Drugs of Abuse Testing Market Size and Forecast By Region
3.2. Global Drugs of Abuse Testing Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing drugs abuse
3.3.1.2. Increasing prevalence of chronic pain
3.3.1.3. Growing demand for drugs of abuse testing in emerging economies
3.3.1.4. Surging investment in drugs of abuse testing
3.3.1.5. Increasing research and developed activates
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Stringent regulation associated with product development
3.3.3. Opportunities
3.3.3.1. Government initiative and awareness program
3.3.3.2. Technological advancements and the modernization in addiction treatment
3.3.4. Challenges
3.3.4.1. Less awareness regarding diagnosis and treatment of Drugs of Abuse in developing nations
3.3.4.2. Short shelf life of products
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Product Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Analyzers
4.1.1.1. Analyzers market size and forecast, 2021-2031 (USD Million)
4.1.2. Rapid Testing Devices
4.1.2.1. Rapid Testing Devices market size and forecast, 2021-2031 (USD Million)
4.1.3. Consumables
4.1.3.1. Consumables market size and forecast, 2021-2031 (USD Million)
4.1.4. Laboratory Services
4.1.4.1. Laboratory Services market size and forecast, 2021-2031 (USD Million)
5. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Sample Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Saliva
5.1.1.1. Saliva market size and forecast, 2021-2031 (USD Million)
5.1.2. Breath
5.1.2.1. Breath market size and forecast, 2021-2031 (USD Million)
5.1.3. Urine
5.1.3.1. Urine market size and forecast, 2021-2031 (USD Million)
5.1.4. Blood
5.1.4.1. Blood market size and forecast, 2021-2031 (USD Million)
5.1.5. Hair
5.1.5.1. Hair market size and forecast, 2021-2031 (USD Million)
5.1.6. Sweat
5.1.6.1. Sweat market size and forecast, 2021-2031 (USD Million)
5.1.7. Others
5.1.7.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Testing Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Onsite Screening Testing
6.1.1.1. Onsite Screening Testing market size and forecast, 2021-2031 (USD Million)
6.1.2. Laboratory Drug Testing
6.1.2.1. Laboratory Drug Testing market size and forecast, 2021-2031 (USD Million)
7. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Alcohol
7.1.1.1. Alcohol market size and forecast, 2021-2031 (USD Million)
7.1.2. Cannabis
7.1.2.1. Cannabis market size and forecast, 2021-2031 (USD Million)
7.1.3. Cocaine
7.1.3.1. Cocaine market size and forecast, 2021-2031 (USD Million)
7.1.4. Opioids
7.1.4.1. Opioids market size and forecast, 2021-2031 (USD Million)
7.1.5. Amphetamine
7.1.5.1. Amphetamine market size and forecast, 2021-2031 (USD Million)
7.1.6. LSD
7.1.6.1. LSD market size and forecast, 2021-2031 (USD Million)
7.1.7. Others
7.1.7.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Geriatric Patient
8.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
8.1.2. Adult Patient
8.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
8.1.3. Pediatric
8.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
9. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Workplaces & Schools
9.1.2.1. Workplaces & Schools market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Criminal Justice Systems & Law Enforcement Agencies
9.1.4.1. Criminal Justice Systems & Law Enforcement Agencies market size and forecast, 2021-2031 (USD Million)
9.1.5. Diagnostics Laboratories
9.1.5.1. Diagnostics Laboratories market size and forecast, 2021-2031 (USD Million)
9.1.6. On-the-spot Testing
9.1.6.1. On-the-spot Testing market size and forecast, 2021-2031 (USD Million)
9.1.7. Forensic Laboratories
9.1.7.1. Forensic Laboratories market size and forecast, 2021-2031 (USD Million)
9.1.8. Others
9.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Direct Tender
10.1.1.1. Direct Tender Market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Sales
10.1.2.1. Retail Sales Market size and forecast, 2021-2031 (USD Million)
11. North America Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Drugs of Abuse Testing Market Size and Forecast By Product Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Drugs of Abuse Testing Market Size and Forecast By Sample Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Drugs of Abuse Testing Market Size and Forecast By Testing Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Drugs of Abuse Testing Market Size and Forecast By Drug Type
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Drugs of Abuse Testing Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Drugs of Abuse Testing Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Drugs of Abuse Testing Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Drugs of Abuse Testing Market Size and Forecast By Product Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Drugs of Abuse Testing Market Size and Forecast By Sample Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Drugs of Abuse Testing Market Size and Forecast By Testing Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Drugs of Abuse Testing Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Drugs of Abuse Testing Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Drugs of Abuse Testing Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Drugs of Abuse Testing Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Drugs of Abuse Testing Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Drugs of Abuse Testing Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Product Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Sample Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Testing Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Drugs of Abuse Testing Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Drugs of Abuse Testing Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Drugs of Abuse Testing Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Drugs of Abuse Testing Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Drugs of Abuse Testing Market Size and Forecast By Product Type
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Drugs of Abuse Testing Market Size and Forecast By Sample Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Drugs of Abuse Testing Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Drugs of Abuse Testing Market Size and Forecast By Testing Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Drugs of Abuse Testing Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
14.9. Brazil Drugs of Abuse Testing Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Drugs of Abuse Testing Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Drugs of Abuse Testing Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Drugs of Abuse Testing Market Size and Forecast By Product Type
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Drugs of Abuse Testing Market Size and Forecast By Sample Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Drugs of Abuse Testing Market Size and Forecast By Testing Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Drugs of Abuse Testing Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Drugs of Abuse Testing Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Drugs of Abuse Testing Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Drugs of Abuse Testing Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Drugs of Abuse Testing Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Drugs of Abuse Testing Market
16.1. F. Hoffmann-La Roche AG
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Siemens Healthineers (Siemens AG)
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Thermo Fisher Scientific, Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Abbott
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Bio-Rad Laboratories Inc.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Drgerwerk ag & co. Kgaa
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Shimadzu Corporation
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Laboratory Corporation of America Holdings
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Danaher
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Express Diagnostics International, Inc.
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Drugs of Abuse Testing Market Drivers & Restraints 2021
Table 7. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 243. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 244. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 245. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 246. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 247. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 248. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 249. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 250. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 251. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 252. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 253. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 254. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 255. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 256. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 257. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 258. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 259. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 260. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 261. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 262. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 263. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 264. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 265. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 266. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 267. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 268. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 269. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 270. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 271. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 272. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 273. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 274. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 275. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 276. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 277. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 278. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 283. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 284. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 285. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 286. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 287. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 288. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 289. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 290. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 291. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 292. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 293. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 294. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 295. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 296. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 297. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 298. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 299. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 300. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 301. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 302. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 303. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 304. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 305. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 306. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 307. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 308. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 309. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 310. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 311. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 312. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 313. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 314. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 315. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 316. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 317. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 318. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 319. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 320. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 321. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 322. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 323. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 324. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 325. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 326. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 327. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 328. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 329. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 330. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 331. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 332. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 333. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 334. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 335. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 336. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 337. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 338. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 339. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 340. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 341. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 342. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 343. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 344. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 345. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 346. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 347. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 348. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 349. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 350. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 351. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 352. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 353. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 354. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 355. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 356. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 357. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 358. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 359. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 360. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 361. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 362. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 363. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 364. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 365. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 366. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 367. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 368. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 369. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 370. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 371. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 372. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 373. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 374. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 375. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 376. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 377. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 378. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 379. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 380. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 381. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 382. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 383. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 384. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 385. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 386. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 387. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 388. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 389. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 390. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 391. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 392. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 393. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 394. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 395. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 396. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 397. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 398. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 399. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 400. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 401. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 402. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 403. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 404. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 405. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 406. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 407. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 408. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 409. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 410. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 411. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 412. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 413. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 414. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 415. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 416. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 417. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 418. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 419. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 420. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 421. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 422. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 423. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 424. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 425. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 426. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 427. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 428. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 429. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 430. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 431. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 432. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 433. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 434. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 435. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 436. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 437. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 438. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 439. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 440. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 441. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 442. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 443. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 444. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 445. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 446. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 447. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 448. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 449. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 450. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 451. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 452. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 453. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 454. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 455. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 456. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 457. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 458. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 459. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 460. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 461. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 462. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 463. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 464. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 465. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 466. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 467. Leading 10 Drugs of Abuse Testing Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 468. F. Hoffmann-La Roche AGProfile 2019 (CEO, HQ, Founded, Website)
Table 469. F. Hoffmann-La Roche AG Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 470. Siemens Healthineers (Siemens AG) Profile 2019 (CEO, HQ, Founded, Website)
Table 471. Siemens Healthineers (Siemens AG) Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 472. Thermo Fisher Scientific, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 473. Thermo Fisher Scientific, Inc. Drugs of Abuse Testing Product Offering (Segment, Product Offerings)
Table 474. Abbott Profile 2019 (CEO, HQ, Founded, Website)
Table 475. Abbott Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 476. Bio-Rad Laboratories Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Bio-Rad Laboratories Inc. Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 478. Drgerwerk ag & co. Kgaa Profile 2019 (CEO, HQ, Founded, Website)
Table 479. Drgerwerk ag & co. Kgaa Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 480. Shimadzu Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 481. Shimadzu Corporation Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 482. Danaher Profile 2019 (CEO, HQ, Founded, Website)
Table 483. Danaher Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 484. Express Diagnostics International, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 485. Express Diagnostics International, Inc. Drugs of Abuse Testing Product Offering (Segment, Product Offerings)
Table 486. Laboratory Corporation of America Holdings Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 487. Laboratory Corporation of America Holdings Drugs of Abuse Testing Product Offering (Segment, Product Offerings)
Table 488. Other Companies Involved in the Drugs of Abuse Testing Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Drugs of Abuse Testing Market Drivers & Restraints 2021
Figure 7. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 8. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 178. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 183. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 188. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 243. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 244. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 245. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 246. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 247. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 248. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 249. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 250. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 251. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 252. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 253. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 254. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 255. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 256. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 257. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 258. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 259. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 260. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 261. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 262. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 263. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 264. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 265. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 266. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 267. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 268. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 269. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 270. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 271. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 272. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 273. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 274. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 275. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 276. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 277. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 278. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 279. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 280. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 281. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 282. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 283. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 284. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 285. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 286. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 287. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 288. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 289. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 290. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 291. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 292. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 293. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 294. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 295. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 296. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 297. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 298. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 299. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 300. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 301. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 302. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 303. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 304. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 305. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 306. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 307. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 308. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 309. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 310. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 311. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 312. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 313. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 314. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 315. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 316. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 317. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 318. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 319. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 320. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 321. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 322. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 323. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 324. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 325. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 326. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 327. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 328. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 329. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 330. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 331. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 332. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 333. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 334. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 335. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 336. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 337. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 338. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 339. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 340. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 341. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 342. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 343. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 344. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 345. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 346. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 347. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 348. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 349. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 350. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 351. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 352. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 353. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 354. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 355. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 356. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 357. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 358. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 359. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 360. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 361. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 362. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 363. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 364. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 365. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 366. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 367. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 368. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 369. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 370. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 371. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 372. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 373. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 374. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 375. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 376. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 377. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 378. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 379. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 380. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 381. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 382. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 383. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 384. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 385. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 386. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 387. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 388. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 389. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 390. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 391. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 392. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 393. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 394. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 395. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 396. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 397. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 398. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 399. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 400. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 401. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 402. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 403. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 404. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 405. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 406. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 407. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 408. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 409. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 410. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 411. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 412. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 413. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 414. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 415. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 416. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 417. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 418. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 419. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 420. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 421. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 422. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 423. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 424. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 425. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 426. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 427. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 428. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 429. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 430. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 431. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 432. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 433. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 434. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 435. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 436. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 437. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 438. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 439. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 440. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 441. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 442. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 443. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 444. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 445. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 446. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 447. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 448. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 449. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 450. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 451. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 452. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 453. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 454. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 455. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 456. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 457. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 458. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 459. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 460. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 461. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 462. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 463. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 464. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 465. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 466. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 467. Porter’s Five Force Analysis
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Drugs of Abuse Testing Market
2.1. Drugs of Abuse Testing Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Application Submarkets Definitions
3. Drugs of Abuse Testing Market Overview
3.1. Global Drugs of Abuse Testing Market Size and Forecast By Region
3.2. Global Drugs of Abuse Testing Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing drugs abuse
3.3.1.2. Increasing prevalence of chronic pain
3.3.1.3. Growing demand for drugs of abuse testing in emerging economies
3.3.1.4. Surging investment in drugs of abuse testing
3.3.1.5. Increasing research and developed activates
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Stringent regulation associated with product development
3.3.3. Opportunities
3.3.3.1. Government initiative and awareness program
3.3.3.2. Technological advancements and the modernization in addiction treatment
3.3.4. Challenges
3.3.4.1. Less awareness regarding diagnosis and treatment of Drugs of Abuse in developing nations
3.3.4.2. Short shelf life of products
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Product Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Analyzers
4.1.1.1. Analyzers market size and forecast, 2021-2031 (USD Million)
4.1.2. Rapid Testing Devices
4.1.2.1. Rapid Testing Devices market size and forecast, 2021-2031 (USD Million)
4.1.3. Consumables
4.1.3.1. Consumables market size and forecast, 2021-2031 (USD Million)
4.1.4. Laboratory Services
4.1.4.1. Laboratory Services market size and forecast, 2021-2031 (USD Million)
5. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Sample Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Saliva
5.1.1.1. Saliva market size and forecast, 2021-2031 (USD Million)
5.1.2. Breath
5.1.2.1. Breath market size and forecast, 2021-2031 (USD Million)
5.1.3. Urine
5.1.3.1. Urine market size and forecast, 2021-2031 (USD Million)
5.1.4. Blood
5.1.4.1. Blood market size and forecast, 2021-2031 (USD Million)
5.1.5. Hair
5.1.5.1. Hair market size and forecast, 2021-2031 (USD Million)
5.1.6. Sweat
5.1.6.1. Sweat market size and forecast, 2021-2031 (USD Million)
5.1.7. Others
5.1.7.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Testing Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Onsite Screening Testing
6.1.1.1. Onsite Screening Testing market size and forecast, 2021-2031 (USD Million)
6.1.2. Laboratory Drug Testing
6.1.2.1. Laboratory Drug Testing market size and forecast, 2021-2031 (USD Million)
7. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Alcohol
7.1.1.1. Alcohol market size and forecast, 2021-2031 (USD Million)
7.1.2. Cannabis
7.1.2.1. Cannabis market size and forecast, 2021-2031 (USD Million)
7.1.3. Cocaine
7.1.3.1. Cocaine market size and forecast, 2021-2031 (USD Million)
7.1.4. Opioids
7.1.4.1. Opioids market size and forecast, 2021-2031 (USD Million)
7.1.5. Amphetamine
7.1.5.1. Amphetamine market size and forecast, 2021-2031 (USD Million)
7.1.6. LSD
7.1.6.1. LSD market size and forecast, 2021-2031 (USD Million)
7.1.7. Others
7.1.7.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Geriatric Patient
8.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
8.1.2. Adult Patient
8.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
8.1.3. Pediatric
8.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
9. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Workplaces & Schools
9.1.2.1. Workplaces & Schools market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Criminal Justice Systems & Law Enforcement Agencies
9.1.4.1. Criminal Justice Systems & Law Enforcement Agencies market size and forecast, 2021-2031 (USD Million)
9.1.5. Diagnostics Laboratories
9.1.5.1. Diagnostics Laboratories market size and forecast, 2021-2031 (USD Million)
9.1.6. On-the-spot Testing
9.1.6.1. On-the-spot Testing market size and forecast, 2021-2031 (USD Million)
9.1.7. Forensic Laboratories
9.1.7.1. Forensic Laboratories market size and forecast, 2021-2031 (USD Million)
9.1.8. Others
9.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Direct Tender
10.1.1.1. Direct Tender Market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Sales
10.1.2.1. Retail Sales Market size and forecast, 2021-2031 (USD Million)
11. North America Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Drugs of Abuse Testing Market Size and Forecast By Product Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Drugs of Abuse Testing Market Size and Forecast By Sample Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Drugs of Abuse Testing Market Size and Forecast By Testing Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Drugs of Abuse Testing Market Size and Forecast By Drug Type
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Drugs of Abuse Testing Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Drugs of Abuse Testing Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Drugs of Abuse Testing Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Drugs of Abuse Testing Market Size and Forecast By Product Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Drugs of Abuse Testing Market Size and Forecast By Sample Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Drugs of Abuse Testing Market Size and Forecast By Testing Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Drugs of Abuse Testing Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Drugs of Abuse Testing Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Drugs of Abuse Testing Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Drugs of Abuse Testing Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Drugs of Abuse Testing Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Drugs of Abuse Testing Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Product Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Sample Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Testing Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Drugs of Abuse Testing Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Drugs of Abuse Testing Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Drugs of Abuse Testing Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Drugs of Abuse Testing Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Drugs of Abuse Testing Market Size and Forecast By Product Type
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Drugs of Abuse Testing Market Size and Forecast By Sample Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Drugs of Abuse Testing Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Drugs of Abuse Testing Market Size and Forecast By Testing Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Drugs of Abuse Testing Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
14.9. Brazil Drugs of Abuse Testing Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Drugs of Abuse Testing Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Drugs of Abuse Testing Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Drugs of Abuse Testing Market Size and Forecast By Product Type
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Drugs of Abuse Testing Market Size and Forecast By Sample Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Drugs of Abuse Testing Market Size and Forecast By Testing Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Drugs of Abuse Testing Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Drugs of Abuse Testing Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Drugs of Abuse Testing Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Drugs of Abuse Testing Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Drugs of Abuse Testing Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Drugs of Abuse Testing Market
16.1. F. Hoffmann-La Roche AG
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Siemens Healthineers (Siemens AG)
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Thermo Fisher Scientific, Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Abbott
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Bio-Rad Laboratories Inc.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Drgerwerk ag & co. Kgaa
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Shimadzu Corporation
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Laboratory Corporation of America Holdings
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Danaher
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Express Diagnostics International, Inc.
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Drugs of Abuse Testing Market Drivers & Restraints 2021
Table 7. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 243. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 244. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 245. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 246. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 247. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 248. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 249. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 250. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 251. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 252. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 253. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 254. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 255. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 256. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 257. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 258. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 259. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 260. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 261. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 262. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 263. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 264. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 265. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 266. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 267. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 268. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 269. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 270. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 271. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 272. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 273. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 274. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 275. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 276. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 277. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 278. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 283. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 284. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 285. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 286. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 287. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 288. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 289. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 290. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 291. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 292. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 293. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 294. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 295. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 296. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 297. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 298. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 299. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 300. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 301. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 302. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 303. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 304. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 305. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 306. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 307. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 308. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 309. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 310. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 311. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 312. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 313. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 314. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 315. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 316. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 317. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 318. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 319. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 320. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 321. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 322. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 323. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 324. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 325. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 326. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 327. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 328. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 329. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 330. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 331. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 332. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 333. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 334. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 335. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 336. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 337. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 338. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 339. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 340. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 341. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 342. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 343. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 344. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 345. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 346. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 347. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 348. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 349. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 350. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 351. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 352. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 353. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 354. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 355. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 356. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 357. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 358. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 359. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 360. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 361. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 362. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 363. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 364. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 365. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 366. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 367. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 368. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 369. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 370. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 371. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 372. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 373. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 374. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 375. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 376. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 377. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 378. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 379. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 380. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 381. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 382. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 383. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 384. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 385. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 386. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 387. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 388. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 389. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 390. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 391. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 392. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 393. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 394. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 395. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 396. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 397. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 398. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 399. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 400. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 401. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 402. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 403. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 404. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 405. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 406. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 407. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 408. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 409. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 410. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 411. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 412. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 413. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 414. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 415. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 416. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 417. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 418. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 419. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 420. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 421. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 422. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 423. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 424. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 425. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 426. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 427. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 428. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 429. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 430. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 431. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 432. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 433. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 434. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 435. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 436. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 437. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 438. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 439. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 440. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 441. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 442. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 443. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 444. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 445. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 446. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 447. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 448. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 449. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 450. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 451. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 452. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 453. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 454. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 455. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 456. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 457. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 458. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 459. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 460. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 461. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 462. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 463. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 464. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 465. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 466. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 467. Leading 10 Drugs of Abuse Testing Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 468. F. Hoffmann-La Roche AGProfile 2019 (CEO, HQ, Founded, Website)
Table 469. F. Hoffmann-La Roche AG Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 470. Siemens Healthineers (Siemens AG) Profile 2019 (CEO, HQ, Founded, Website)
Table 471. Siemens Healthineers (Siemens AG) Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 472. Thermo Fisher Scientific, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 473. Thermo Fisher Scientific, Inc. Drugs of Abuse Testing Product Offering (Segment, Product Offerings)
Table 474. Abbott Profile 2019 (CEO, HQ, Founded, Website)
Table 475. Abbott Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 476. Bio-Rad Laboratories Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Bio-Rad Laboratories Inc. Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 478. Drgerwerk ag & co. Kgaa Profile 2019 (CEO, HQ, Founded, Website)
Table 479. Drgerwerk ag & co. Kgaa Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 480. Shimadzu Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 481. Shimadzu Corporation Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 482. Danaher Profile 2019 (CEO, HQ, Founded, Website)
Table 483. Danaher Drugs of Abuse Product Offering (Segment, Product Offerings)
Table 484. Express Diagnostics International, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 485. Express Diagnostics International, Inc. Drugs of Abuse Testing Product Offering (Segment, Product Offerings)
Table 486. Laboratory Corporation of America Holdings Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 487. Laboratory Corporation of America Holdings Drugs of Abuse Testing Product Offering (Segment, Product Offerings)
Table 488. Other Companies Involved in the Drugs of Abuse Testing Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Drugs of Abuse Testing Market Drivers & Restraints 2021
Figure 7. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 8. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 178. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 183. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 188. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 243. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 244. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 245. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 246. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 247. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 248. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 249. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 250. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 251. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 252. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 253. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 254. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 255. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 256. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 257. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 258. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 259. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 260. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 261. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 262. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 263. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 264. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 265. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 266. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 267. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 268. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 269. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 270. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 271. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 272. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 273. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 274. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 275. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 276. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 277. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 278. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 279. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 280. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 281. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 282. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 283. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 284. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 285. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 286. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 287. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 288. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 289. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 290. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 291. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 292. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 293. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 294. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 295. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 296. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 297. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 298. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 299. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 300. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 301. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 302. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 303. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 304. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 305. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 306. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 307. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 308. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 309. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 310. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 311. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 312. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 313. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 314. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 315. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 316. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 317. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 318. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 319. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 320. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 321. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 322. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 323. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 324. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 325. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 326. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 327. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 328. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 329. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 330. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 331. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 332. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 333. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 334. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 335. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 336. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 337. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 338. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 339. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 340. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 341. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 342. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 343. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 344. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 345. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 346. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 347. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 348. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 349. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 350. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 351. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 352. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 353. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 354. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 355. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 356. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 357. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 358. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 359. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 360. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 361. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 362. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 363. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 364. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 365. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 366. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 367. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 368. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 369. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 370. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 371. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 372. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 373. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 374. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 375. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 376. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 377. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 378. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 379. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 380. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 381. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 382. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 383. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 384. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 385. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 386. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 387. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 388. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 389. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 390. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 391. Middle East Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 392. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 393. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 394. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 395. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 396. Middle East Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 397. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 398. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 399. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 400. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 401. Latin America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 402. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 403. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 404. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 405. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 406. Latin America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 407. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 408. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 409. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 410. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 411. Latin America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 412. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 413. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 414. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 415. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 416. Latin America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 417. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 418. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 419. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 420. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 421. Latin America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 422. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 423. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 424. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 425. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 426. Latin America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 427. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 428. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 429. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 430. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 431. Latin America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 432. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 433. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 434. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 435. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 436. Africa Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 437. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 438. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 439. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 440. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 441. Africa Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 442. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 443. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 444. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 445. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 446. Africa Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 447. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 448. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 449. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 450. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 451. Africa Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 452. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 453. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 454. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 455. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 456. Africa Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 457. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 458. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 459. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 460. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 461. Africa Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 462. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 463. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 464. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 465. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 466. Africa Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 467. Porter’s Five Force Analysis
Companies Profiled in the Report
1. F. Hoffmann-La Roche AG
2. Siemens Healthineers (Siemens AG)
3. Thermo Fisher Scientific, Inc.
4. Abbott
5. Bio-Rad Laboratories Inc.
6. Drgerwerk ag & co. Kgaa
7. Shimadzu Corporation
8. Laboratory Corporation of America Holdings
9. Danaher
10. Express Diagnostics International, Inc.
List of Companies Mentioned in the Report:
1. BD
2. Abbott
3. AbbVie Inc.
4. ACON Laboratories Inc.
5. AdvaCare Pharma
6. ARKRAY USA, Inc.
7. Atomo Diagnostics
8. Avecon Healthcare Pvt Ltd
9. Beckman Coulter, Inc. ( a subsidiary of Danaher)
10. Biohit Oyj
11. bioLytical Laboratories Inc.
12. BIOMEDOMICS INC
13. bioMérieux SA
14. Bio-Rad Laboratories, Inc.
15. BODITECH MED INC.
16. Chembio Diagnostic Systems, Inc.
17. Chembio Diagnostic Systems, Inc.
18. Chembio Diagnostic Systems, Inc.
19. Diagenode Diagnostics
20. Diagnosis S.A.
21. DiaSorin S.p.A.
22. EKF Diagnostics Holdings plc
23. F. Hoffmann-La Roche Ltd
24. Germaine Laboratories, Inc.
25. Gilead Sciences, Inc.
26. Gilead Sciences, Inc.
27. Grifols, S.A
28. Hemosure, Inc.
29. Hologic, Inc.
30. HUMASIS.
31. Illumina, Inc.
32. Janssen Global Services, LLC
33. Johnson & Johnson Services, Inc.
34. Lamdagen Corporation
35. LifeSign LLC.
36. Maccura Biotechnology Co., Ltd.
37. Medixbiochemica
38. Merck & Co., Inc.
39. Merck KGaA
40. MicroGen Diagnostics
41. Mylan N.V.
42. Nova Biomedical
43. Nanoentek
44. OraSure Technologies, Inc.
45. PerkinElmer Inc.
46. PointCare
47. QIAGEN
48. Quidel Corporation
49. Sannuo Biosensing Co., Ltd.
50. Siemens Healthcare GmbH
List of Organizations Mentioned in the Report:
1. Agência Nacional de Vigilância Sanitária (ANVISA)
2. Duke University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
1. F. Hoffmann-La Roche AG
2. Siemens Healthineers (Siemens AG)
3. Thermo Fisher Scientific, Inc.
4. Abbott
5. Bio-Rad Laboratories Inc.
6. Drgerwerk ag & co. Kgaa
7. Shimadzu Corporation
8. Laboratory Corporation of America Holdings
9. Danaher
10. Express Diagnostics International, Inc.
List of Companies Mentioned in the Report:
1. BD
2. Abbott
3. AbbVie Inc.
4. ACON Laboratories Inc.
5. AdvaCare Pharma
6. ARKRAY USA, Inc.
7. Atomo Diagnostics
8. Avecon Healthcare Pvt Ltd
9. Beckman Coulter, Inc. ( a subsidiary of Danaher)
10. Biohit Oyj
11. bioLytical Laboratories Inc.
12. BIOMEDOMICS INC
13. bioMérieux SA
14. Bio-Rad Laboratories, Inc.
15. BODITECH MED INC.
16. Chembio Diagnostic Systems, Inc.
17. Chembio Diagnostic Systems, Inc.
18. Chembio Diagnostic Systems, Inc.
19. Diagenode Diagnostics
20. Diagnosis S.A.
21. DiaSorin S.p.A.
22. EKF Diagnostics Holdings plc
23. F. Hoffmann-La Roche Ltd
24. Germaine Laboratories, Inc.
25. Gilead Sciences, Inc.
26. Gilead Sciences, Inc.
27. Grifols, S.A
28. Hemosure, Inc.
29. Hologic, Inc.
30. HUMASIS.
31. Illumina, Inc.
32. Janssen Global Services, LLC
33. Johnson & Johnson Services, Inc.
34. Lamdagen Corporation
35. LifeSign LLC.
36. Maccura Biotechnology Co., Ltd.
37. Medixbiochemica
38. Merck & Co., Inc.
39. Merck KGaA
40. MicroGen Diagnostics
41. Mylan N.V.
42. Nova Biomedical
43. Nanoentek
44. OraSure Technologies, Inc.
45. PerkinElmer Inc.
46. PointCare
47. QIAGEN
48. Quidel Corporation
49. Sannuo Biosensing Co., Ltd.
50. Siemens Healthcare GmbH
List of Organizations Mentioned in the Report:
1. Agência Nacional de Vigilância Sanitária (ANVISA)
2. Duke University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
Download sample pages
Complete the form below to download your free sample pages for Drugs of Abuse Testing Market Report 2021-2031Related reports
-
Plasma Therapy Market Report 2021-2031
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma...Full DetailsPublished: 16 November 2020 -
Cold Laser Therapy Market Report 2021-2031
Prevalence of chronic and non-chronic diseases is increasing significantly due to rapidly changing lifestyle and increased consumption of malnutrition and...
Full DetailsPublished: 01 January 1970 -
Track and Trace Solutions Market Report 2021-2031
The key factors driving the growth of this market include the severe regulations & principles for the implementation of serialization,...
Full DetailsPublished: 01 January 1970 -
Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity...Full DetailsPublished: 24 November 2020 -
Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical...Full DetailsPublished: 25 September 2020 -
Antinuclear Antibody Test Market Report to 2031
Where is the Global Antinuclear Antibody Test market heading? If you are involved in this sector you must read this...Full DetailsPublished: 01 January 1970 -
Antibiotic Residue Test Kits Market Report to 2031
Where is the Antibiotic Residue Test Kit market heading? If you are involved in this sector you must read this...Full DetailsPublished: 01 January 1970 -
Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing...Full DetailsPublished: 24 November 2020 -
Automated Immunoassay Analysers Market Report to 2031
Where is the Automated Immunoassay Analyzers market heading? If you are involved in this sector you must read this newly...Full DetailsPublished: 01 January 1970 -
Tissue Diagnostics Market Report 2021-2031
Where the Tissue Diagnostics market is heading? If you are involved in this industry you must read this newly updated...
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Drugs of Abuse Testing Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
